ABUS
Arbutus BiopharmaBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
11
U.S. public peers
Grade Position
In line
vs peer average
ABUS vs peer average
69/100
ABUS vs. peer average (B vs. C)
Grade spread
A 1 · B 3 · C 2 · D 3 · F 2
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
ELVN is the first available peer comparator.
Clinical-stage biotech of similar market cap and development financing profile; helps calibrate program-risk premium.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
ABUS
Arbutus Biopharma
ELVN
Enliven Therapeutics
Grade
B
B
Momentum
54
73
Value
41
41
Sentiment
77
58
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Constructive
Constructive
Grade position vs ELVN
ABUS / ELVN
Grade Position
In line
ABUS vs. peer average (B vs. C)
69/100
Momentum
54
ELVNValue
41
ABUSSentiment
77
ABUSRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs ABUS
ELVN is the first peer returned for this comparison set.